BGT Biopharma

BGT Biopharma is a Swiss-based biopharmaceutical company dedicated to the development and commercialization of high-quality biosimilars and innovative therapeutic proteins. The company focuses on high-value biological products in the areas of oncology, immunology, and neurology, with a primary emphasis on monoclonal antibodies. Its lead pipeline candidates include biosimilar versions of blockbuster drugs such as ocrelizumab and rituximab, aimed at treating multiple sclerosis and various cancers. BGT Biopharma utilizes a lean business model and strategic clinical partnerships to navigate the regulatory pathways in Europe and other global markets. By providing cost-effective alternatives to reference biologics, the company seeks to improve patient access to essential life-changing treatments.